Sustained virological response to interferon‐α is associated with improved outcome in HCV‐related cirrhosis: A retrospective study

By S. Bruno, T. Stroffolini, M. Colombo, S. Bollani, L. Benvegnu', G. Mazzella, A. Ascione, T. Santantonio, F. Piccinino, P. Andreone and 5 more. Hepatology, 2007

604 citations recorded by the source corpus.

Subfields: Hepatology

View Paper: https://www.semanticscholar.org/paper/5eb19a25b8da833e1c07449d5738c0348c458051

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. M. Kudo
2. A. Cheng

Citations in the corpus

• Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017, background): “Patients who achieve sustained HBV-DNA suppression or HBeAg seroconversion in chronic HBV and SVR in chronic HCV have increased; however, those treatments do not eliminate the risk of HCC completely [405, 406].”
• Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma (2013, neutral): “Braks et al, 2007 (37) Bruno et al, 2007 (38) Cardoso et al, 2010 (40) Hasegawa et al, 2007 (64) Hung et al, 2006 (65) Morgan et al, 2010 (52) van der Meer et al, 2012 (63) Velosa et al, 2011 (60) Total Heterogeneity: tau-square = 0.00; chi-square = 3.64; P = 0.82; I2 = 0% Test for overall effect:…”